Want to join the conversation?
Biopharma company $GILD said 2 Phase 3 trials, Studies 108 and 110, evaluating once-daily TAF 25 mg in adults with HBeAg-negative and HBeAg-positive chronic HBV infection met their primary endpoints of non-inferiority versus Viread 300 mg. TAF also showed improved renal and bone lab safety parameters versus Viread.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.